Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Latest Information Update: 25 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 22 Apr 2025 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 07 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
- 28 Mar 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.